Cutler Group’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-3,000
Closed -$412K 3833
2022
Q4
$450K Buy
3,000
+912
+44% +$140K 0.04% 482
2022
Q3
$281K Sell
2,088
-575
-22% -$87.9K 0.02% 802
2022
Q2
$397K Sell
2,663
-30,333
-92% -$4.63M 0.03% 629
2022
Q1
$5.63M Buy
32,996
+20,429
+163% +$3.43M 0.3% 62
2021
Q4
$3.24M Buy
12,567
+8,667
+222% +$2.37M 0.14% 159
2021
Q3
$1.06M Buy
3,900
+194
+5% +$61.7K 0.05% 433
2021
Q2
$829K Sell
3,706
-3,104
-46% -$585K 0.04% 530
2021
Q1
$743K Buy
6,810
+3,207
+89% +$341K 0.04% 558
2020
Q4
$293K Buy
3,603
+2,003
+125% +$197K 0.01% 874
2020
Q3
$110K Buy
+1,600
New +$115K 0.01% 1256

Other funds holding BNTX

Cutler Group's BNTX Position: Q1 2023 in Review

Cutler Group sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 3,000 shares — an estimated $412K sold.

Cutler Group first reported a position in BNTX in Q3 2020 and held it in 10 quarters. The position peaked at $5.63M in Q1 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

  • Cutler Group reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 3,000 BioNTech shares in Q1 2023, an estimated $412K.
  • Cutler Group first reported a position in BioNTech in Q3 2020 and held it in 10 quarters.
  • Cutler Group's BioNTech position peaked at $5.63M in Q1 2022.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.